Small Molecule sEH Inhibitors to Treat Alpha-Synuclein Neurodegenerative Disorders

Tech ID: 29327 / UC Case 2018-474-0


Researchers at the University of California, Davis have developed small molecule inhibitors to prevent or reverse the progression of neurodegenerative diseases or symptoms.

Full Description

Current diagnosis of Parkinson’s disease (PD), a chronic and progressive neurodegenerative disorder, has connections to the deposition of specific protein aggregates termed Lewy bodies. There are several PD symptoms commonly associated with these protein aggregates including palsy and dementia. Although there are multiple treatments for PD, these medications do not stop or reverse the progression of the disease.

Researchers at the University of California, Davis have developed soluble epoxide hydrolase (sEH) inhibitors for the treatment of neurodegenerative disorders. The inhibitors may block the phosphorylation of alpha-synuclein, which plays a key role in the pathogenesis of alpha-synuclein-related neurodegenerative diseases, reducing endoplasmic reticulum stress and possibly prevent the aggregation of Lewy bodies. The small molecule inhibitors are capable of preventing or reversing the progression of neurodegenerative diseases and symptoms.


  • Mitigating, delaying or preventing α-synuclein-related neurodegenerative disorders
    • Parkinson's disease, dementia, Alzheimer’s, ALS, palsy, tramatic brain injury and neurodegeneration


  • Decreases inflammation associated with the pathogenesis of PD
  • Reduces endoplasmic reticulum stress
  • May have a role in preventing the aggregation of Lewy bodies

Related Materials

Patent Status

Patent Pending


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Hammock, Bruce D.
  • Hwang, Sung Hee

Other Information


small molecule, inhibitors, soluble epoxide hydrolase, sEH, alpha-synuclein, neurodegenerative disorders, parkinson's, lewy bodies, a-synuclein

Categorized As